Hear from and meet with the leading figures in precision oncology to explore how companies are innovating in precision medicine, digital pathology and molecular testing to accelerate timelines and reduce risk in drug development, with in-depth consideration of the latest multiplexed and cytometry tools impacting biomarker research & validation
NextGen Omics 2023 features 4 outstanding programmes, bringing together Europe’s most successful omics research experts under one roof. The series provides an excellent networking platform which consists of key discussion topics in: Next Generation Sequencing & Clinical Diagnostics, Single Cell & Spatial Analysis, Synthetic Biology in Discovery & Therapeutics and Digital PCR & Liquid Biopsies
Associate Professor at Biology, Waubonsee Community College, IL. I am a Bio QUEST curriculum consortium fellow, contributor to the development of the Scientific Teaching Course from the National Institute of Scientific Teaching (NIST) and Editorial Board member for CBE-Life Sciences Education (LSE) journal.My doctoral training is in Pharmacology and Molecular biology. Recently, my scholarship has shifted to science education. I enjoy working with all students, especially freshman/sophomores from diverse backgrounds in biology education research projects in the aspects of effective study strategies and metacognition. I am passionate about implementing Course -Based Undergraduate Experiences (CUREs) with the lens of a quantitative data literacy to foster inclusion in a community college classroom. I continue to use project based assignments and data interpretation modules with scientific contributions of scientists who are members of historically excluded groups. Teaching is the way I connect with people, especially young people. I learn so much from them in trying to figure out how to help them learn.I enjoyed co-leading the first ASCN Inclusive STEM Teaching Project ASCN Learning community in 2021. In my workings with various groups, I learned the skills of building learning communities to foster shared common goals and attitudes while promoting an equitable participation of all members. It gave me a platform to bring the voices of the community college landscape with STEM practitioners from other institution types. The opportunities to be informed by the lived perspectives from different stakeholders, led me to ponder about the aspects of implementing and scaling change. I see myself as a change agent at the grassroots level.
I am a Research Instructor at the University of Nebraska Medical Center’s Eppley Institute for Cancer Research, hosted by the labs of Dr. Michael (Tony) Hollingsworth (cancer biology, immunology) and Dr. Ken Bayles (bacterial genetics, microbiology). During my doctoral studies, I became fascinated with the many advantages oncolytic bacteria have over traditional therapeutics. As a result, I pursued specific training in genetic engineering and anaerobic bacteria. I performed ground-breaking studies, accomplishing the first CRISPR-mediated modification of Clostridium novyi-NT and established methodologies that have added to the field of biologic therapeutics. I chose post-doctorate studies at UNMC to further my training in immunology, cancer models, bacterial genetics, and microbiology. My long-term career goal is to establish a diverse and equitable academic research lab focused on genetically engineering single celled organisms for pharmaceutical and biofuel development. Additionally, I ascribe to the teacher/scholar model and intend to use my expertise to generate graduate and undergraduate courses as well as to mentor students in a laboratory setting – while fostering inclusive environments in both circumstances.
Hear from and meet with the leading figures in biomarker analysis to explore how companies are innovating in biomarker analysis to accelerate timelines and reduce risk in drug development, with in-depth consideration of the latest multiplexed and cytometry tools impacting biomarker research & validation.
Key Speakers:
Mario Richter – AbbVie Deutschland GmbH & Co. KG
Eike Staub – Merck
Siôn Lewis – UCB BioPharma
Li Chin Wong – Prevail Therapeutics
Priyank Patel – Boehringer Ingelheim
Polina Goihberg – Pfizer
My career dedication to biotechnology education and the growth of the bioeconomy is best exemplified by my involvement with iGEM – over a decade with roles spanning volunteer, team mentor, judge, and After-iGEM committee member. After earning my PhD in Molecular Biology from Stony Brook University in 2013, I taught biology and mentored teams at both Kingsborough Community College in Brooklyn (New York City) and at Alma College, in rural-mid Michigan. Currently I am involved in growing the bioeconomy from a different vantage point as a Synthetic Biologist at the University of Dayton Research Institute. However, I am also continuing educational outreach and community building through the Great Lakes SynBio Association. GLSB is a nonprofit I co-founded that is dedicated to the growth of the bioeconomy in the Midwestern US. I was recently selected as a ‘Next Generation Leader’ at the ‘Spirit of Asilomar and Future of Biotechnology’ summit. I’ve seen firsthand both the awesome power biotechnology has to motivate students, as well as the waning participation and excellence the US has in iGEM first, and eventually the field writ large.
Apart from time in the lab or meetings (at UDRI or beyond), you can find me spending time with my wife and two daughters (9yo and 8mo). I am also an avid chess and tennis player, a member of the Society of Catholic Scientists, and an ardent Mets fan.
European Center of Sustainable Development in collaboration with Canadian Institute of Technology will organize the 11th ICSD 2023 International Conference on Sustainable Development, with particular focus on Environmental, Economic and Socio-Cultural Sustainability.
The Conference theme : Creating a unified foundation for the Sustainable Development: Research, Practice and Education.
The 11th ICSD 2023 will be an excellent opportunity to share your ideas and research findings relevant to the Sustainability Science, through the European network of academics.
Papers will be published in Open Access EJSD Journal (Web of Science) and Proceedings..
This ambition will proceed in a multidisciplinary way across the various fields and perspectives, through which we can address the fundamental and related questions of Sustainable Development.
Join leaders, experts and researchers at West Coast’s scientific Hub – San Diego, delivering breakthrough research, technologies & connecting global pharma, biotech and academia for high-level discussions on the latest innovations in formulation, drug delivery & inhaled science.
Formulation & Delivery US 2023 features 2 outstanding programmes, bringing together key opinion leaders under one roof. The events provide a unique networking platform which consists of vital discussion topics in: Formulation & Drug Delivery and Inhalation & Respiratory Drug Delivery.
Speakers Include:
Arvinder Dhalla (Vice President, Clinical Development, Rani Therapeutics)
Charlie (Xiaolin) Tang (Director in Formulation Development, Regeneron)
Gian Luca Araldi (Founder and Chief Executive Officer, Avanti Biosciences)
Grace Yu (President & Chief Executive Officer, Trilogy Therapeutics)
Stephen Pham (Vice President, Product Development, Avalyn Pharma)
Theresa Scheuble (Head of Enterprise Design & Innovation, Johnson & Johnson)
Dr. Jorge Marchand is an Assistant Professor at the University of Washington in the Department of Chemical Engineering. He did his PhD work at the University of California, Berkeley in the research group of Michelle Chang, where he worked on the discovery of biosynthetic pathways for making terminal alkyne amino acids. His postdoctoral work was done at Harvard Medical School with the George Church group. Here, he focused on engineering translation and developing new sequencing technologies to study tRNA. He now runs an independent research group that aims to utilize fundamental approaches in synthetic biology, chemical biology, biosynthesis, and biomolecular engineering for reprogramming life at the nucleic acid level.
Discuss the latest strategies to harness the immune system for the development of innovative therapeutics
Gain a US perspective on the latest technologies and novel biomarkers driving forward translational research and precision medicine
Dr. Ania-Ariadna Baetica is an Assistant Professor in the Department of Mechanical Engineering and Mechanics at Drexel University. She received her BA degree from Princeton University in 2012 and her PhD from California Institute of Technology in 2018. Following her degrees, she was a postdoctoral scholar at the University of California San Francisco.
Dr. Baetica’s group leverages control theory along with systems biology, synthetic biology, and computational science to solve biotechnological and medical challenges. Her group designs robust and modular synthetic biological circuits by incorporating layered feedback mechanisms.
My lab studies how genomes encode organisms’ phenotypes. To do this, we use techniques from genetics, molecular systems biology, and synthetic biology. In the area of synthetic biology, we have developed new approaches for building synthetic chromosomes from natural DNA.
Join RNA leaders, experts and distinguished scientists in Europe, delivering breakthrough research, technologies & connecting global pharma, biotech and academia for high-level discussions on the latest innovations within the formulation and delivery of RNA-based therapeutics.
Join oligo leaders, experts and distinguished scientists in Europe, delivering breakthrough research, technologies & connecting global pharma, biotech and academia for high-level discussions on the latest innovations within the oligonucleotides chemistry & therapeutics development.
I’m a new faculty at Texas A&M studying synthetic biology and control theory. Before moving to Texas, I completed four years of postdoctoral training in the Richard Murray Group at Caltech. I received my Ph.D. in Chemical and Biomolecular Engineering from Cornell University in 2018, advised by Julius B. Lucks.
Gene Therapy Development & Manufacturing 2023 delivers in-depth discussion on optimised process strategies and technologies for the successful technical development and manufacture of advanced gene therapy products.
I am a Research Assistant Professor at the Department of Electrical and Computer Engineering (ECE) and the director of the Oliveira Lab (www.oliveiralab.me), a recently created research group at Boston University (BU). In addition, I am the Senior Manager of the DAMP lab (www.damplab.org) at BU.
The Oliveira lab investigates the emergence of microbial community complexity and their underlying interactions in varying environmental contexts and studies microbial community design principles and metrics to help build novel collective behaviors. We hope that breakthroughs in computational and synthetic biology methods will accelerate our knowledge of the links between genetic sequences and intercellular communication to study and engineer the spatiotemporal behavior of biological networks. Among my key collaborators: i) Prof. Chris Voigt (MIT) for improving the predictive DNA design automation tool named Cello (Genetic Circuit Design Automation with Cello 2.0. Nature Protocols).
In my early career, I have published more than 30 articles in journals, conference proceedings, and book chapters, acted as the guest Editor for JoVE, and as a reviewer for Nat. Comm., ACS Synth. Biol., Synth. Biol. J., among others. In addition, I have directly supervised and co-supervised 7 research staff, 7 graduate students (none of whom received their Ph.D. with me), 3 master’s students, and over 14 undergraduates. I was one of the recipients of the Sao Paulo Foundation’s Best Innovative Biotech Product Award in 2019. Based on that, I co-founded a commercial synthetic biology, automation-based company named Doroth (www.doroth.com.br) in Brazil.
Currently, with the support from a $1.4M NSF grant, BU’s Professor Douglas Densmore (co-PI), Prof. Andrews (PI) from UMass Amherst, and my team (technical lead support) are teaming up on an ambitious effort to create microscopic, programmable “living devices” which can detect and neutralize specific toxic contaminants found in drinking water.
Bringing together leading omics experts from around the world and comprised of three outstanding programmes, delegates can expect to benefit from critical discussions in the future of Next Generation Sequencing, Multi-omic Single Cell & Spatial Analyses and Genome editing in Drug Discovery and Therapeutic Development.
The 2023 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.
Below are some of the confirmed speakers of NextGen Omics US 2023.
Timothy Dahlem, Director of Systems Biology at Recursion Pharmaceuticals
Kamel Khalili, Laura H. Carnell Professor and Chair Lewis Katz School of Medicine at Temple University
Kalina Hristova, Professor of Materials Science and Engineering Institute for NanoBioTechnology at John Hopkins University
Guo-Cheng Yuan, Professor of Computational Biology at Icahn School of Medicine at Mount Sinai
Tirtha Chakraborty, Chief Scientific Officer at Vor Biopharma
Sandra Smieszek, Head of Genetics at Vanda Pharmaceuticals
The main research interest of Dr. Ahmed is to focus on industrially important metabolites production in microbes through the application of system metabolic engineering and synthetic biology. Previously, Dr. Ahmed developed industrially competitive microbial strains that were capable of producing industrially important secondary metabolites, for instance, β-amyrin, squalene, etc., and these strains are highly efficient for commercialization. Moreover, Dr. Ahmed expanded his research interest toward other industrially important metabolites, i.e., fragrance, flavor, and drugs, that might be in the category of alkaloids, sesquiterpenoids, monoterpenoids, diterpenoids, triterpenoids, and tetraterpenoids. These metabolites are normally used in pharmaceuticals, nutraceuticals, and cosmeceuticals industries as raw materials for the production of medicines, foods, and cosmetics.